Last reviewed · How we verify

NCT01836744

Survival Rate of Dental Implants Placed in Sinus Lift Performed With Two Different Grafts

Completed Phase 4 Last updated 13 September 2023
What this trial tests

Phase 4 trial testing Survival rate dental implant (OsseoSpeed™) in Dental Implant Survival Rate in 12 participants. Completed in 30 July 2023.

Timeline
18 March 2013
Primary endpoint
20 June 2017
30 July 2023

Quick facts

Lead sponsorGrupo de Investigação: Cirurgia Oral, Peridontologia, Implantologia
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment12
Start date18 March 2013
Primary completion20 June 2017
Estimated completion30 July 2023
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Grupo de Investigação: Cirurgia Oral, Peridontologia, Implantologia

Who can join

18 and older, any sex, with Dental Implant Survival Rate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous in a randomized way, it will be performance 12 bilateral sinus lift with autologous bone in one side and the in other with xenograft material. After 6 mouths we will place 1 to 3 implants in each side and analyse the survival rate and possibles differences related to; prosthesis failure; biological and prosthetic complications; peri-implant marginal bone level changes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Advantages of Porcine Xenograft over Autograft in Sinus Lift: A Randomised Clinical Trial.
    Correia F, Pozza DH, Gouveia S, Felino AC, et al · · 2021 · cited 20× · PMID 34205826 · DOI 10.3390/ma14123439
  2. A Randomized Clinical Trial Comparing Implants Placed in Two Different Biomaterials Used for Maxillary Sinus Augmentation.
    Correia F, Gouveia SA, Pozza DH, Felino AC, et al · · 2023 · cited 7× · PMID 36770223 · DOI 10.3390/ma16031220
  3. Maxillary Sinus Augmentation with Xenogenic Collagen-Retained Heterologous Cortico-Cancellous Bone: A 3-Year Follow-Up Randomized Controlled Trial.
    Correia F, Gouveia S, Felino AC, Faria-Almeida R, et al · · 2024 · cited 5× · PMID 38392237 · DOI 10.3390/dj12020033

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01836744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing